BERKELEY HEIGHTS, N.J., Jan. 20, 2011 (GLOBE NEWSWIRE) -- Genta Incorporated (OTCBB:GNTA) announced today the appointments of Ana I. Stancic and Dr. Marvin E. Jaffe, MD, as members of the Company's Board of Directors. The Company also announced the retirement from the Board of Mr. Douglas G. Watson.
Dr. Raymond P. Warrell, Jr., Genta's Board Chairman and Chief Executive Officer commented: "The Genta team is delighted to welcome our new independent directors. Ms. Stancic's breadth of experience in finance, accounting, compliance, and business development should greatly enhance the Board's financial guidance. Dr. Jaffe's long track record of successful drug development should provide pivotal insights into a year wherein we complete a pivotal Genasense program and initiate the new Phase 3 program with tesetaxel."
"The Board extends our deepest gratitude to Doug Watson, who has served on the Genta Board for the past 8 years. During his tenure, Doug's counsel, judgment, wisdom and guidance to his colleagues have been invaluable, and we wish him continued success with his myriad endeavors."Ana I. Stancic Ms. Stancic brings extensive and diversified finance and accounting experience from a long career in healthcare and biotechnology. She is currently senior vice president and chief financial officer at M2Gen, a wholly owned, for-profit subsidiary of the Moffitt Cancer Center, where she provides direction, leadership, and management for all financial operations, controls, internal audits, and facility administration. Previously, she was Chief Financial Officer of Aureon Bioscience, Inc., an oncology diagnostic company. From 2007 to 2008, she was Executive Vice President and Chief Financial Officer at OMRIX Biopharmaceuticals, Inc., which was acquired by Johnson and Johnson. From 2004 to 2007, Ms. Stancic was at ImClone Systems, Inc., which was acquired by Eli Lilly, Inc. At ImClone, she served in various financial roles, including Senior Vice President, Finance. Prior to joining ImClone, she was Vice President and Controller at Savient Pharmaceuticals, Inc. Ms. Stancic began her career at PricewaterhouseCoopers in the Assurance practice where she had responsibility for international and national companies in the pharmaceutical and services industries. Ms. Stancic is a Certified Public Accountant and holds an M.B.A. degree from Columbia University Graduate School of Business School. She currently serves as a member of the Board of Directors of Champions Biotechnology, Inc. and KV Pharmaceutical Co.